FDA Breakthrough Therapy Designation Granted To Clovis Oncology’s CO-1686 Non Small Cell Lung Cancer Drug
Lung Cancer
Patients with non small cell lung cancer (NSCLC), the most prevalent form of lung cancer, face a dismal five-year survival rate of less than 5%. Almost 85% of the 1.7 ... Read more